| Guo, Hui |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
NCT06336954: Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure |
|
|
| Not yet recruiting | 2 | 40 | NA | Adibelimab, Famitinib, Chemotherapy | Second Affiliated Hospital of Xi'an Jiaotong University | Non Small Cell Lung Cancer | 07/24 | 12/26 | | |
NCT06662760: Clinical Trial of TQB3002 in Patients With Advanced Cancers |
|
|
| Not yet recruiting | 1 | 120 | RoW | TQB3002 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 10/25 | 10/26 | | |
NCT04734067: Exploration of the Predictive Marker and Establishment of Predictive Models of Checkpoint Inhibitor Pneumonitis |
|
|
| Not yet recruiting | N/A | 440 | NA | Immune checkpoint inhibitors(ICIs) therapy | First Affiliated Hospital Xi'an Jiaotong University, Tang-Du Hospital, The First Affiliated Hospital of Zhengzhou University, Henan Cancer Hospital, Wuhan Union Hospital, China, Fujian Cancer Hospital | Pneumonia, Interstitial | 02/24 | 02/25 | | |
